NCT00151762已完成3 期
A Multi-Center, 52-Week, Open-Label Extension Study (From Studies WEL-301, WEL-302, and WEL-303) to Evaluate the Long-Term Safety and Tolerability of WelChol® in Type 2 Diabetic Patients
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 780
- 试验地点
- 64
- 主要终点
- To evaluate safety and tolerability of colesevelam hydrochloride as add-on therapy
研究概览
简要总结
This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
To evaluate safety and tolerability of colesevelam hydrochloride as add-on therapy
次要结局
- To assess the long-term effect on hemoglobin A1c
- To assess the long-term effect on fasting plasma glucose
- To assess effects on lipids and lipoproteins
研究者
研究点 (64)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular DegenerationNeovascular Age-related Macular DegenerationNCT04777201Hoffmann-La Roche1,036
已完成
3 期
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesNCT04164199BeOne Medicines404
已完成
3 期
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular EdemaDiabetic Macular EdemaNCT04432831Hoffmann-La Roche1,479
终止
2 期
Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor FluctuationsParkinson's DiseaseNCT01634360Eisai Inc.185
已完成
3 期
A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset SeizuresEpilepsyNCT01777139GlaxoSmithKline30